Superworth

Corcept Therapeutics price to free cash flow CORT

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026
86.8×
10-year median
19.3×
Against its 10-year history
97th
percentile: 0 is its lowest day, 100 its highest
10-year range
8.4× to 124×
Peer median
46.0×

Corcept Therapeutics' price to free cash flow is 86.8× as of Oct 23, 2026.

That is above its ten-year median of 19.3×, higher than on 97% of days in the last ten years.

Over that time it ranged from 8.4× in Aug 2020 to 124× in Aug 2026.

The median for 10 large drugmakers of a similar size is 46.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far86.8×22.5×124×
202553.5×40.3×56.9×
202429.7×14.4×29.7×
202321.7×16.3×25.5×
202216.1×11.3×21.0×
202115.0×14.2×20.8×
202018.5×8.4×19.2×
201913.0×9.7×17.4×
201812.7×11.7×71.3×
201751.3×41.7×68.0×
201645.1×45.1×181×

Against its peers

Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
CORTCorcept Therapeutics86.8×
PTGXProtagonist Therapeutics68.6×
TGTXTG Therapeutics477×
BMRNBiomarin Pharmaceutical14.7×
ALKSAlkermes plc.33.0×
AMRXAmneal Pharmaceuticals50.9×
JAZZJazz Pharmaceuticals8.7×
LGNDLigand Pharmaceuticals46.0×
KNSAKiniksa Pharmaceuticals International32.7×
INDVIndivior Pharmaceuticalsn/m
ARQTArcutis Biotherapeutics100×
Peer median46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Corcept Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.